MYH14

Across TCGA pan-cancer cohorts, MYH14 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MYH14’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MYH14 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYH14 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where MYH14 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYH14 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.921	<.001	11	view →
HNSC	All	II,III,IV	−0.728	<.001	11	view →
PDAC	All	III,IV	+0.848	<.001	10	view →
LUAD	Female	III,IV	−1.012	<.001	9	view →
LSCC	Male	All	−0.939	<.001	8	view →
COAD	All	II,III,IV	+0.195	.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MYH14–CCRCC

Open the CCRCC breakdown →